| 產(chǎn)品編號(hào) | bs-5799R |
| 英文名稱 | BAG3 Rabbit pAb |
| 中文名稱 | Bcl2抑凋亡蛋白Bag3抗體 |
| 別 名 | BAG 3; BAG family molecular chaperone regulator 3; BAG-3; Bag3; BAG3_HUMAN; y Bcl 2 binding protein; Bcl-2-associated athanogene 3; Bcl-2-binding protein Bis; BCL2 associated athanogene 3; BCL2 binding athanogene 3; BIS; Docking protein CAIR 1; Docking protein CAIR-1. |
 |
Specific References (1) | bs-5799R has been referenced in 1 publications.
[IF=1.763] Jie Wei. et al. The Regulation of Prototype Foamy Virus 5′Long Terminal Repeats and Internal Promoter by Endogenous Transcription Factors. Intervirology. ;:1-12 WB ; Human.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 細(xì)胞凋亡 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | (predicted: Human,Mouse,Rat,Rabbit,Pig,Sheep,Cow,Chicken,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 61 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BAG3: 441-540/575 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Has anti-apoptotic activity. Function: Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Has anti-apoptotic activity. Subunit: Binds to the ATPase domain of HSP/HSC70 chaperones. Binds to Bcl-2 and PLC-gamma. Interacts with DNAJB6. DISEASE: Defects in BAG3 are the cause of myopathy myofibrillar type 6 (MFM6) [MIM:612954]. A neuromuscular disorder that results in early-onset, severe, progressive, diffuse muscle weakness associated with cardiomyopathy, severe respiratory insufficiency during adolescence, and a rigid spine in some patients. At ultrastructural level, muscle fibers display structural alterations consisting of replacement of the normal myofibrillar markings by small, dense granules, or larger hyaline masses, or amorphous material. Defects in BAG3 are the cause of cardiomyopathy dilated type 1HH (CMD1HH) [MIM:613881]. CMD1HH is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Similarity: Contains 1 BAG domain. Contains 2 WW domains. SWISS: O95817 Gene ID: 9531 Database links: Entrez Gene: 9531 Human Entrez Gene: 29810 Mouse Omim: 603883 Human SwissProt: O95817 Human SwissProt: Q9JLV1 Mouse Unigene: 523309 Human Unigene: 84073 Mouse Unigene: 46304 Rat |
